1. Human CD3+CD56+NKT-like cells express a range of complement receptors and C3 activation has negative effects on these cell activity and effector function
- Author
-
Xiao Yang, Ting Zhang, Ke Li, Ning Ma, Bo Cao, Xiaoyun Min, Na Wang, and Cheng-Fei Liu
- Subjects
0301 basic medicine ,education.field_of_study ,Complement component 3 ,biology ,CD46 ,Chemistry ,CD3 ,Immunology ,Population ,hemic and immune systems ,chemical and pharmacologic phenomena ,General Medicine ,Complement receptor ,Complement system ,Complement (complexity) ,Cell biology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Immune system ,biology.protein ,Immunology and Allergy ,education ,030215 immunology - Abstract
CD3+CD56+NKT-like cells are a rare population of lymphocytes that serve important roles in various types of immune-related diseases, and particularly in cancer. The complement system regulates inflammatory and immune responses by interacting with complement receptors expressed on a range of immune cells. However, whether CD3+CD56+NKT-like cells are regulated by the complement system has still not been definitively determined. In the present study, the expression of complement receptors and regulators in gated CD3+CD56+NKT-like cells isolated from human peripheral blood was assessed using PCR and flow cytometry. The results showed that human CD3+CD56+NKT-like cells expressed a range of complement receptors and regulators, such as CR3, C3aR, C5aR, C5L2, CD46 and CD55. Furthermore, the presence of complement component 3 (C3), a key component in complement activation in culture supernatant, mitigated the activity, IFN-γ production and killing function of CD3+CD56+NKT-like cells. The present study provides evidences supporting the relationship between complement activation and functional modulation of CD3+CD56+NKT-like cells, expanding our knowledge of the complement regulatory network, and also highlighting a potential target for treatment of numerous immune-related diseases, particularly NKT cell-based tumor adoptive immunotherapy.
- Published
- 2021